

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
	Applicant Kiyotaka Nakano <i>et al.</i>		
	Filing Date April 18, 2007	Group Art Unit 1641	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	5,077,216	12/31/1991	Morganelli <i>et al.</i>			
	2	5,223,241	06/29/1993	Isobe <i>et al.</i>			
	3	5,747,654	05/05/1998	Pastan <i>et al.</i>			
	4	6,132,992	10/17/2000	Ledbetter <i>et al.</i>			
	5	7,691,588	04/06/2010	Tsuchiya <i>et al.</i>			
	6	2002/0155537	10/24/2002	Carter <i>et al.</i>			
	7	2004/0219643	11/04/2004	Winter <i>et al.</i>			
	8	2005/0214278	09/29/2005	Kakuta <i>et al.</i>			
	9	2005/0267222	12/01/2005	Iwata <i>et al.</i>			
	10	2006/0058511	03/16/2006	Tanikawa <i>et al.</i>			
	11	2006/0159673	07/20/2006	Kojima			
	12	2006/0269989	11/30/2006	Miyazaki <i>et al.</i>			
	13	2007/0087381	04/19/2007	Kojima			
	14	2009/0214535	08/27/2009	Igawa <i>et al.</i>			
	15	2009/0297501	12/03/2009	Igawa <i>et al.</i>			
	16	2010/0015133	01/21/2010	Igawa <i>et al.</i>			
	17	2010/0092457	04/15/2010	Aburatani <i>et al.</i>			
	18	2011/0059488	03/10/2011	Tsunoda <i>et al.</i>			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	19	AU 2002/210917	05/18/2006	Australia			X	
	20	CA 2272245	05/28/1998	Canada				
	21	CA 2 331 641	11/11/1999	Canada				
	22	EP 437 622	07/24/1991	Europe				
	23	EP 0562125	09/29/1993	Europe				
	24	EP 0 774 511	05/21/1997	Europe				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1641

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	25	EP 811 691	12/10/1997	Europe				
	26	EP 1 870 458	12/26/2007	Europe				
	27	EP 1 900 814	03/19/2008	Europe				
	28	DE 198 19 846	11/11/1999	Germany			Abstract only	
	29	JP 3-41033	02/21/1991	Japan			Abstract only	
	30	JP 8-500979	02/06/1996	Japan			Abstract only	
	31	JP 2001-523971	11/27/2001	Japan			Abstract only	
	32	JP 2002-543822	12/24/2002	Japan			Abstract only	
	33	JP 2003-515323	05/07/2003	Japan			Abstract only	
	34	JP 2004-292455	10/21/2004	Japan			Abstract only	
	35	WO 91/00739	01/24/1991	WIPO				
	36	WO 93/06862	04/15/1993	WIPO			English abstract	
	37	WO 94/05690	03/17/1994	WIPO				
	38	WO 96/27011	09/06/1996	WIPO				
	39	WO 96/34892	11/07/1996	WIPO				
	40	WO 97/10354	03/20/1997	WIPO			English abstract	
	41	WO 98/22136	05/28/1998	WIPO			English abstract	
	42	WO 98/50431	11/12/1998	WIPO				
	43	WO 00/44788	08/03/2000	WIPO				
	44	WO 00/069462	11/23/2000	WIPO				
	45	WO 01/036486	05/25/2001	WIPO				
	46	WO 01/44282	06/21/2001	WIPO				
	47	WO 01/70775	09/27/2001	WIPO				
	48	WO 02/096457	12/05/2002	WIPO				
	49	WO 03/033538	04/24/2003	WIPO			English abstract	
	50	WO 03/086324	10/23/2003	WIPO				

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1641

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	51	WO 03/087163	10/23/2003	WIPO			English abstract	
	52	WO 2004/019966	03/11/2004	WIPO			English abstract	
	53	WO 2004/037293	05/06/2004	WIPO			English abstract	
	54	WO 2004/111233	12/23/2004	WIPO			English abstract	
	55	WO 2005/107784	11/17/2005	WIPO			English abstract	

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	56	ANDRIS-WIDHOPF <i>et al.</i> , "Methods for the generation of chicken monoclonal antibody fragments by phage display," <i>Journal of Immunological Methods</i> , 242:159-181 (2000)
	57	ARNDT <i>et al.</i> , "Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment," <i>Biochemistry</i> , 37(37):12918-26 (1998)
	58	ARNDT <i>et al.</i> , "Generation of a highly stable, internalizing anti-DC22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma," <i>Int. J. Cancer</i> , 107(5):822-829 (2003)
	59	CARPENTER <i>et al.</i> , "Rational design of stable lyophilized protein formulations: some practical advice," <i>Pharmaceutical Research</i> , 14(8):969-975 (1997)
	60	CARPENTER <i>et al.</i> , "Rational design of stable lyophilized protein formulations: theory and practice," <i>Pharma Biotechnol.</i> , 13:109-133 (2001)
	61	CARTER, "Bispecific human IgG by design," <i>J. Immunol. Methods</i> , 248:7-15 (2001)
	62	CEKAITE <i>et al.</i> , "Protein Arrays: A versatile toolbox for target identification and monitoring of patient immune responses," <i>Methods Mol. Biol.</i> , 360:335-348 (2007)
	63	CHATELLIER <i>et al.</i> , "Functional mapping of conserved residues located at the VL and VH domain interface of a Fab," <i>J. Mol. Biol.</i> , 264(1):1-6 (1996)
	64	CHOWDHURY <i>et al.</i> , "Engineering scFvs for improved stability," <i>Methods Mol. Biol.</i> , 207:237-54 (2003)
	65	CLACKSON <i>et al.</i> , "Making antibody fragments using phage display libraries," <i>Nature</i> , 352:624-628 (1991)
	66	CLELAND <i>et al.</i> , "A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody," <i>Journal of Pharmaceutical Sciences</i> , 90(3):310-321 (2001)
	67	COCHLOVIUS <i>et al.</i> , "Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells," <i>The Journal of Immunology</i> , 165:888-895 (2000)
	68	CREIGHTON, T., "Protein folding," <i>Biochem. J.</i> , 270(1):1-16 (1990)
	69	DAVIES <i>et al.</i> , "Antibody VH domains as small recognition units," <i>Biotechnology (N.Y.)</i> , 13(5):475-9 (1995)
	70	DE JONGE <i>et al.</i> , "Production and Characterization of Bispecific Single-Chain Antibody Fragments," <i>Mol. Immunol.</i> , 32:1405-1412 (1995)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1641

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	71	EIJSINK <i>et al.</i> , "Rational engineering of enzyme stability," <i>Journal of Biotechnology</i> , 113:105-120 (2004)
	72	EWERT <i>et al.</i> , "Biophysical properties of human antibody variable domains," <i>J. Mol. Biol.</i> , 325:531-553 (2003)
	73	EWERT <i>et al.</i> , "Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering," <i>Methods</i> , 34:184-199 (2004)
	74	EWERT <i>et al.</i> , "Structure-based improvement of the biophysical properties of immunoglobulin V <sub>H</sub> domains with a generalizable approach," <i>Biochemistry</i> , 42:1517-1528 (2003)
	75	FROKJAER <i>et al.</i> , "Protein drug stability: a formulation challenge," <i>Nature Rev Drug Discov.</i> , 4:298-306 (2005)
	76	GARCIA-GONZALEZ <i>et al.</i> , "Purification of murine IgG3 and IgM monoclonal antibodies by euglobulin precipitation," <i>Journal of Immunological Methods</i> , 111:17-23 (1988)
	77	GenBank: U27005.1, <i>Mus musculus</i> , isolate 7183Liv, Vh7183 Ig heavy chain variable region gene, Vh region, partial cds, 1 page (April 1996)
	78	GenBank: AY081858.1, <i>Mus musculus</i> , isolate H3-9 anti-GBM immunoglobulin kappa chain variable region mRNA, partial cds, 1 page (March 2004)
	79	GOLDSTEIN <i>et al.</i> , "Cytolytic and Cytostatic Properties of an Anti-Human FcγRI (CD64) × Epidermal Growth Factor Bispecific Fusion Protein," <i>J. Immunol.</i> , 158:872-879 (1997)
	80	GOMBOTZ <i>et al.</i> , "The stabilization of a human IgM monoclonal antibody with poly(vinylpyrrolidone)," <i>Pharmaceutical Research</i> , 11(5):624-632 (1994)
	81	GRUBER <i>et al.</i> , "Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in <i>Escherichia coli</i> ," <i>Journal of Immunology</i> , 152:5368-5374 (1994)
	82	HOOGENBOOM <i>et al.</i> , "Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains," <i>Nucleic Acids Res.</i> , 19:4133-4137 (1991)
	83	HOZUMI and TONEGAWA, "Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions," <i>Proc. Natl. Acad. Sci. USA</i> , 73(10):3628-3632 (1976)
	84	JÄGER <i>et al.</i> , "Folding and assembly of an antibody Fv fragment, a heterodimer stabilized by antigen," <i>Journal of Molecular Biology</i> , 285:2005-2019 (1999)
	85	JUNG <i>et al.</i> , "The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibody V(H) domains," <i>J. Mol. Biol.</i> , 309(3):701-16 (2001)
	86	KHALIFA <i>et al.</i> , "Effects on interaction kinetics of mutations at the VH-VL interface of Fabs depend on the structural context," <i>J. Mol. Recognit.</i> , 13(3):127-39 (2000)
	87	KIPRIYANOV and LITTLE, "Generation of Recombinant Antibodies," <i>Molecular Biotechnology</i> , 12:173-201 (1999)
	88	KIPRIYANOV <i>et al.</i> , "Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics," <i>Journal of Molecular Biology</i> , 293:41-56 (1999)
	89	KONTERMANN, R., "Recombinant bispecific antibodies for cancer therapy," <i>Acta Pharmacol. Sin.</i> , 26(1):1-9 (2005)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1641

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	90	KORN <i>et al.</i> , "Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv," <i>The Journal of Gene Medicine</i> , 6:642-651 (2004)
	91	KREBBER <i>et al.</i> , "Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system," <i>J. Immunol. Methods</i> , 201:35-55 (1997)
	92	KURUCZ <i>et al.</i> , "Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria," <i>The Journal of Immunology</i> , 154:4576-4582 (1995)
	93	LE GALL <i>et al.</i> , "Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody," <i>Protein Engineering Design &amp; Selection</i> , 17(4):357-366 (2004)
	94	LEE <i>et al.</i> , "Reversible dimer formation and stability of the anti-tumour single chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FR-IR spectroscopy," <i>J. Mol. Biol.</i> , 320:107-127 (2002)
	95	LITTLE <i>et al.</i> , "Of mice and men: hybridoma and recombinant antibodies," <i>Immunol. Today</i> , 21:364-370 (2000)
	96	LIU <i>et al.</i> , "Functional interactions between arginine-133 and aspartate-88 in the human reduced folate carrier: evidence for a charge-pair association," <i>Biochem. J.</i> , 358:511-516 (2001)
	97	MAITY <i>et al.</i> , "Equilibrium unfolding of dimeric and engineered monomeric forms of Cro (F58W) repressor and the effect of added salts: evidence for the formation of folded monomer induced by sodium perchlorate," <i>Archives of Biochemistry and Biophysics</i> , 434:93-107 (2005)
	98	MARTSEV <i>et al.</i> , "Antiferritin single-chain antibody: a functional protein with incomplete folding?" <i>FEBS Letters</i> , 441:458-462 (1998)
	99	MCGUINNESS <i>et al.</i> , "Phage diabody repertoires for selection of large number of bispecific antibody fragments," <i>Nature Biotechnology</i> , 14(9):1149-1154 (1996)
	100	MENG <i>et al.</i> , "The evaluation of recombinant, chimeric, tetravalent antihuman CD22 antibodies," <i>Clinical Cancer Research</i> , 10:1274-1281 (2004)
	101	MERCHANT <i>et al.</i> , "An efficient route to human bispecific IgG," <i>Nature Biotechnology</i> , 16:677-681 (1996)
	102	NIEBA <i>et al.</i> , "Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved <i>in vivo</i> folding and physical characterization of an engineered scFv fragment," <i>Protein Engineering</i> , 10(4):435-444 (1997)
	103	NOHAILE <i>et al.</i> , "Altering dimerization specificity by changes in surface electrostatics," <i>PNAS</i> 98(6):3109-3114 (2001)
	104	PEIPP <i>et al.</i> , "Bispecific antibodies targeting cancer cells," <i>Biochem. Soc. Trans.</i> , 30:507-511 (2002)
	105	RAJAGOPAL <i>et al.</i> , "A form of anti-Tac (Fv) which is both single-chain and disulfide stabilized: comparison with its single-chain and disulfide-stabilized homologs," <i>Protein Engineering</i> , 10(12):1453-1459 (1997)
	106	RIDGWAY <i>et al.</i> , "'Knobs-into-holes' engineering of antibody C <sub>H</sub> 3 domains for heavy chain heterodimerization," <i>Protein Eng.</i> , 9:617-621 (1996)
	107	ROUSCH <i>et al.</i> , "Somatostatin displayed on filamentous phage as a receptor-specific agonist," <i>Br. J. Pharmacol.</i> , 125:5-16 (1998)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1641

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	108	SEGAL <i>et al.</i> , "Bispecific antibodies in cancer therapy," <i>Current Opinion in Immunology</i> , 11:558-582 (1999)
	109	SHALABY <i>et al.</i> , "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," <i>J. Exp. Med.</i> , 175:217-225 (1992)
	110	SHARMA <i>et al.</i> , "Study of IgM aggregation in serum of patients with macroglobulinemia," <i>Clin Chem Lab Med</i> , 38(8):759-764 (2000)
	111	SHIMBA <i>et al.</i> , "Comparative thermodynamic analyses of the Fv, Fab* and Fab fragments of anti-dansyl mouse monoclonal antibody," <i>FEBS Letters</i> , 360:247-250 (1995)
	112	SHIRE <i>et al.</i> , "Challenges in the development of high protein concentration formulations," <i>Journal of Pharmaceutical Sciences</i> , 93(6):1390-1402 (2004)
	113	SKERRA, "Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in <i>Escherichia coli</i> ," <i>Gene</i> , 151:131-135 (1994)
	114	TAN <i>et al.</i> , "Contributions of a highly conserved V <sub>H</sub> /V <sub>L</sub> hydrogen bonding interaction to scFv folding stability and refolding efficiency," <i>Biophysical Journal</i> , 75:1473-1482 (1998)
	115	TANG <i>et al.</i> , "Selection of linkers for a catalytic single-chain antibody using phage display technology," <i>The Journal of Biological Chemistry</i> , 271(26):15682-15686 (1996)
	116	TURNER <i>et al.</i> , "Importance of the linker in expression of single-chain Fv antibody fragments: optimization of peptide sequence using phage display technology," <i>Journal of Immunological Methods</i> , 205:43-54 (1997)
	117	VAN DEN BURG <i>et al.</i> , "Selection of mutations for increased protein stability," <i>Curr. Opin. Biotechnol.</i> , 13(4):333-337 (2002)
	118	VARGAS-MADRAZO <i>et al.</i> , "An improved model of association for VH-VL immunoglobulin domains: asymmetries between VH and VL in the packing of some interface residues," <i>J. Mol. Recognit.</i> , 16(3):113-20 (2003)
	119	VIEILLE <i>et al.</i> , "Hyperthermophilic enzymes: sources, uses, and molecular mechanisms for thermostability," <i>Microbiology and Molecular Biology Reviews</i> , 65(1):1-43 (2001)
	120	VOLKEL <i>et al.</i> , "Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies," <i>Protein Engineering</i> , 14(10):815-823 (2001)
	121	WANG <i>et al.</i> , "Instability, stabilization, and formulation of liquid protein pharmaceuticals," <i>International Journal of Pharmaceutics</i> , 185:129-188 (1999)
	122	WANG <i>et al.</i> , "Lyophilization and development of solid protein pharmaceuticals," <i>International Journal of Pharmaceutics</i> , 203:1-60 (2000)
	123	WANG <i>et al.</i> , "Protein aggregation and its inhibition in biopharmaceutics," <i>International Journal of Pharmaceutics</i> , 289:1-30 (2005)
	124	WHITLOW <i>et al.</i> , "An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability," <i>Protein Engineering</i> , 6(8):989-995 (1993)
	125	WORN <i>et al.</i> , "Stability engineering of antibody single-chain Fv fragments," <i>J. Mol. Biol.</i> , 305:989-1010 (2001)
	126	WU <i>et al.</i> , "Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange," <i>Protein Eng.</i> , 14(12):1025-33 (2001)
	127	ZHU <i>et al.</i> , "Remodeling domain interfaces to enhance heterodimer formation," <i>Protein Science</i> , 6:781-788 (1997)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1641

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	128	ZHU <i>et al.</i> , "An efficient route to the production of an IgG-like bispecific antibody", <i>Protein Eng.</i> , 13:361-367 (2000)
	129	FISH & RICHARDSON, Amendment in Reply to Action dated April 23, 2010 in U.S. App. Ser. No. 10/530,696, filed October 22, 2010, 8 pages
	130	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed January 7, 2011, 10 pages
	131	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Notice of Allowance in U.S. App. Ser. No. 10/551,504, mailed December 16, 2010, 5 pages
	132	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Notice of Allowance in U.S. App. Ser. No. 10/551,504, mailed March 21, 2011, 7 pages
	133	FISH & RICHARDSON P.C., Amendment in Reply to Action dated April 16, 2010 in U.S. App. Ser. No. 10/582,413, filed October 15, 2010, 11 pages
	134	U.S. EXAMINER BRADLEY DUFFY, USPTO Final Office Action in U.S. App. Ser. No. 10/582,413, mailed December 23, 2010, 12 pages
	135	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,304, mailed December 9, 2010, 12 pages
	136	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Restriction Requirement in U.S. App. Ser. No. 12/874,872, mailed December 15, 2010, 6 pages
	137	FISH & RICHARDSON P.C., Reply to Restriction Requirement dated December 15, 2010 in U.S. App. Ser. No. 12/874,872, filed January 18, 2011, 8 pages
	138	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 11/910,117, mailed May 3, 2010, 9 pages
	139	FISH & RICHARDSON P.C., Amendment and Response to Restriction Requirement mailed May 3, 2010 in U.S. App. Ser. No. 11/910,117, filed November 2, 2010, 11 pages
	140	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/910,117, mailed January 24, 2011, 10 pages
	141	International Search Report for App. Ser. No. PCT/JP2006/306800, mailed May 16, 2006, 4 pages
	142	International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/306800, dated October 3, 2007, 6 pages
	143	European Search Report for App. Ser. No. EP 06 73 0748, dated April 22, 2009, 7 pages
	144	KLARQUIST SPARKMAN, LLP, Amendment in Reply to Action dated September 1, 2009 in U.S. App. Ser. No. 10/582,654, filed February 26, 2010, 11 pages
	145	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Final Office Action in U.S. App. Ser. No. 10/582,654, mailed April 6, 2010, 15 pages
	146	KLARQUIST SPARKMAN, LLP, Amendment in Reply to Action dated April 6, 2010 in U.S. App. Ser. No. 10/582,654, filed September 21, 2010, 7 pages

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	